SCYNEXIS, Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
SCYNEXIS, Inc. (SCYX) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$4.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-04
- SCYNEXIS, Inc. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2015-12-31 was -$8.39M.
- SCYNEXIS, Inc. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2015-09-30 was -$7.53M.
- SCYNEXIS, Inc. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2014-12-31 was -$3.63M.
- SCYNEXIS, Inc. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2014-09-30 was -$4.54M.
- SCYNEXIS, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$4.70M.
- SCYNEXIS, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$20.50M.
- SCYNEXIS, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2016 was -$29.99M.
- SCYNEXIS, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2015 was -$28.34M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 3 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 6 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 9 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|---|---|---|
| 2025-12-31 | -$4.70M 10-K · filed 2026-03-04 | |||
| 2024-12-31 | -$20.50M 10-K · filed 2026-03-04 | |||
| 2016-12-31 | -$29.99M 10-K · filed 2017-03-13 | |||
| 2015-12-31 | -$8.39M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-13 | -$15.92M derived: sum of 2 quarters · filed 2017-03-13 | -$28.34M 10-K · filed 2017-03-13 | |
| 2015-09-30 | -$7.53M 10-Q · filed 2015-11-13 | -$19.95M 10-Q · filed 2015-11-13 | ||
| 2014-12-31 | -$3.63M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-13 | -$8.17M derived: sum of 2 quarters · filed 2017-03-13 | -$6.77M 10-K · filed 2017-03-13 | |
| 2014-09-30 | -$4.54M 10-Q · filed 2015-11-13 | -$3.13M 10-Q · filed 2015-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |